Data availability This study used population-level aggregate and de-identified data collected by the TriNetX Platform and are available from TriNetX, LLC ( but third-party restrictions apply to the availability of these data
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist that reduces appetite hormonally, slows gastric emptying, and produces 1520% body weight reduction in clinical trials even without structured dietary intervention
SeekPeptides members access comprehensive tracking tools, protocol databases, and community insights that help optimize GLP-1 treatment from the first dose through long-term maintenance
Remarkably, cognitive improvements were most noticeable in individuals with a higher body mass index or obesity
Eating small, frequent meals of protein and healthy fat slows gastric emptying further, paradoxically reducing nausea in some patientscounterintuitive because slower stomach movement should worsen it, but the protective effect of adequate nutrition outweighs this